Stockhub

Aldeyra Therapeutics, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

13 August 2022

11 August 2022

26 July 2022

  • curprev 15:5915:59, 26 July 2022‎ 172.18.0.2 talk‎ 1,138 bytes +1,138‎ Created page with "Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma,..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Aldeyra_Therapeutics,_Inc.’